Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $19.79 USD
Change Today -1.12 / -5.36%
Volume 125.5K
LOXO On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 2:27 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

loxo oncology inc (LOXO) Snapshot

Open
$21.16
Previous Close
$20.91
Day High
$21.60
Day Low
$18.63
52 Week High
07/28/15 - $21.74
52 Week Low
01/21/15 - $9.90
Market Cap
330.2M
Average Volume 10 Days
88.5K
EPS TTM
$-3.06
Shares Outstanding
16.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LOXO ONCOLOGY INC (LOXO)

Related News

No related news articles were found.

loxo oncology inc (LOXO) Related Businessweek News

No Related Businessweek News Found

loxo oncology inc (LOXO) Details

Loxo Oncology, Inc. engages in the discovery, development, and commercialization of cancer therapies in the United States. Its lead product candidate includes LOXO-101, an oral and selective inhibitor of tropomyosin receptor kinase (TRK), which is in a Phase I dose escalation trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company’s preclinical programs include RET inhibitor that optimizes potency for RET fusion proteins, mutations, and clinically-identified resistance mutations; FGFR inhibitor that optimizes on potency against receptors comprising four isoforms with tyrosine kinase domains; and FLT3 inhibitor that optimizes on potency for the FLT3 internal tandem duplication mutations. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets. The company was founded in 2013 and is headquartered in Stamford, Connecticut.

13 Employees
Last Reported Date: 05/14/15
Founded in 2013

loxo oncology inc (LOXO) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $350.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $189.7K
Compensation as of Fiscal Year 2014.

loxo oncology inc (LOXO) Key Developments

University of Colorado Cancer Center and Loxo Oncology, Inc. Announce Publication of Clinical Validation for LOXO-101 Against TRK Fusion Cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc. announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development. The peer-reviewed research brief describes a female patient with advanced soft tissue sarcoma widely metastatic to the lungs. The patient's physician submitted a tumor specimen to Foundation Medicine for comprehensive genomic profiling with FoundationOne Heme, where her cancer was demonstrated to harbor a TRK gene fusion. Following multiple unsuccessful courses of treatment, the patient was referred to the University of Colorado for enrollment in the Phase 1 trial of LOXO-101 in March 2015. On study, the patient's shortness of breath rapidly resolved and she was able to discontinue her supplemental oxygen and resume activities of daily living. Imaging studies following one month of treatment, the first imaging studies conducted post-treatment, confirmed that her tumors had substantially regressed, meeting a partial response (PR) definition by standard RECIST 1.1 criteria. As discussed in the publication, with four months of treatment, additional CT scans demonstrated almost complete tumor disappearance of the large tumors. After four months of dosing, the patient did not have any adverse events that were attributed to LOXO-101. The publication also describes novel assays for assessing LOXO-101's impact on TRK signaling, patient-derived TRK fusion models in vitro and in vivo which illustrate LOXO-101's TRK inhibition, and the first-ever description of the molecular epidemiology of TRK fusions in soft tissue sarcoma. LOXO-101, built specifically to inhibit TRK, is currently being studied in a Phase 1 trial of patients with advanced solid tumors. The trial continues to enroll patients at escalating oral doses of fixed once-daily and twice-daily regimens. As reported at the 2015 American Association for Cancer Research (AACR) meeting, LOXO-101 has been well tolerated with no drug-related adverse event signals reported at doses that consistently achieve systemic drug exposures anticipated to inhibit TRK signaling by over 90%. For more information on the Phase 1 trial, including study sites and eligibility criteria, visit clinicaltrials.gov (study identifier NCT02122913), or contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123. LOXO-101 is a potent, oral, selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules. The TRK family (TRKA, TRKB, and TRKC) has been implicated in diverse tumor types such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-101 was built specifically to inhibit TRK and is currently the only selective TRK inhibitor in clinical development. LOXO-101 is currently being evaluated in a Phase 1 dose escalation trial for patients with advanced solid tumors.

Loxo Oncology, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 11:30 AM

Loxo Oncology, Inc. Presents at JMP Securities Life Sciences Conference, Jun-24-2015 11:30 AM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Joshua H. Bilenker, Founder, Chief Executive Officer, President and Director.

Loxo Oncology, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Loxo Oncology, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net loss attributable to common shareholders of $6.2 million and $2.9 million for the first quarters 2015 and 2014, respectively. Net loss per share of common stock, basic and diluted was $0.38 compared to $14.22 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LOXO:US $19.79 USD -1.12

LOXO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LOXO.
View Industry Companies
 

Industry Analysis

LOXO

Industry Average

Valuation LOXO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LOXO ONCOLOGY INC, please visit www.loxooncology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.